Recruiting Sjogrens Syndrome Studies in Glendale
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep....
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1. To evaluate the effect of ...
About Sjogrens Syndrome Clinical Trials in Glendale
Sjogren's syndrome is a chronic autoimmune disorder in which the immune system attacks the glands that produce moisture, causing dry eyes and dry mouth. It can also affect joints, thyroid, kidneys, and other organs. Treatment focuses on relieving symptoms and may include immunosuppressive medications.
There are currently 2 sjogrens syndrome clinical trials recruiting participants in Glendale, CALIFORNIA. These studies are seeking a combined 1,279 participants. Research is being sponsored by Amgen. Clinical trial participation is free and participants receive study-related medical care at no cost.
Sjogrens Syndrome Clinical Trials in Glendale — FAQ
Are there sjogrens syndrome clinical trials in Glendale?
Yes, there are 2 sjogrens syndrome clinical trials currently recruiting in Glendale, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Glendale?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Glendale research site will contact you about next steps.
Are clinical trials in Glendale free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Glendale studies also compensate for your time and travel.
What sjogrens syndrome treatments are being tested?
The 2 active trials in Glendale are testing new therapies including novel drugs, biologics, and treatment approaches for sjogrens syndrome.
Data updated March 2, 2026 from ClinicalTrials.gov